Capricor Therapeutics, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (29)

Latest Posts

About This Stock More About This Stock
E The Dream Team Disruptors - Einstein's In Biopharma 2020-2021
Article By: James Gornick
Tuesday, November 24, 2020 7:18 AM EST
The trends in the final months of 2020 and moving into 2021 have assembled "The Dream-Team" in saving many lives and the losses in functionalities in those infected with COVID-19 World-Wide Pandemic.
In this article: AZN, JNJ, PFE, CYDY, ABIO, REGN, SPPI, MRNA, AXDX, CAPR, MESO, NVS Also: INO, SRNE, NVAX, DVAX, CRSP
Read
E Blockbuster SAR-CoV2 Disrupters Pre-ICU / Admitted ICU Patient Treatments & COVID-19 T-Cell Vaccine Horizon
Article By: James Gornick
Wednesday, July 22, 2020 5:50 AM EST
In recent months, there has been a flurry of activity within the clinical trial sector. When all trial types are considered, there are over 400 studies exploring approaches to diagnosing, treating, or preventing COVID-19.
In this article: CAPR, ATHX Also: BMRN, AZN, PFE, INO, NVAX, REGN, XLY, MRNA, BNTX, SRNE
Read
E Capricor Therapeutics Tumbles 60% On Failed Heart Attack Trial
Article By: Terry Chrisomalis
Friday, May 12, 2017 12:15 PM EST
Capricor Therapeutics reported an update on its phase 2 trial known as Allstar. It stated that the drug, CAP-1002 showed a low probability of achieving the primary endpoint of the study.
In this article: CAPR
Read
Biotech Digest – JAZZ Reports Positive Results, CTSO Inks New Contract, AMGN Forges Collaboration
Article By: KKD Healthcare Analytics
Tuesday, April 25, 2017 10:15 AM EST
Capricor Therapeutics announced encouraging six-month results in a Phase 1/2 clinical trial. Jazz Pharmaceuticals reported results from its Phase 2/3 clinical trial. Amgen announced its new collaboration with Novartis.
In this article: NVS, EAPH, ACHN, JAZZ, AMGN, CANF, CAPR, CTSO
Read

Latest Tweets for $CAPR

No tweets yet!